Heterocycle compounds

1. A compound of Formula 1

wherein

R 1 is selected from the group consisting of hydrogen, C 1-12 alkyl, C 3-10 cycloalkyl, arylalkyl, heterocyclyl, heterocycloalkyl, heteroarylalkyl, cycloalkenyl, C 2-12 fluoroalkyl, C 3-10 alkoxy, and heteroalkyl, with the proviso that the carbon atoms that are bonded to the nitrogen are not aromatic or carbonyl;

R 2 is selected from the group consisting of C 3-12 alkyl, C 3-10 cycloalkyl, arylalkyl, heterocyclyl, heterocycloalkyl, heteroarylalkyl, cycloalkenyl, C 3-12 fluoroalkyl, C 3-10 alkoxy, and heteroalkyl, with the proviso that the carbon atoms that are bonded to the nitrogen are not aromatic or carbonyl;

R 1 and R 2 may optionally be joined to form a ring;

A is attached in the meta or para position with respect to the diarylether linker and is a C 1-3 alkylene;

R 3 and R 4 are each independently selected from the group consisting of —H, —F, —Cl, —Br, —OH, —OC 1-3 alkyl, —C 1-3 fluoroalkyl, and —C 1-3 alkyl;

X, Y, and Z are each independently selected from the group consisting of —N, —NH, —CH, —O, —S, —NR 5 , and —CR 6 , wherein R 5 and R 6 are each independently a C 1-6 alkyl or a fluoroalkyl; and

a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein A is a methylene attached in the para position with respect to the diarylether linker.

3. The compound of claim 2 wherein R 1 is hydrogen; R 2 is selected from the group consisting of arylmethyl, arylethyl, C 4-10 alkyl, cycloalkenyl, cycloalkyl, heteroalkyl, heteroaryl methyl, heteroarylethyl, heterocyclylmethyl, and heterocyclylethyl; R 3 and R 4 are each independently selected from the group consisting of H, methyl, and F.

4. The compound of claim 3 wherein either X or Z is —NH with the other being —CH or —N; and wherein Y is —CH or —N.

5. The compound of claim 1 wherein the compound of Formula 1 is selected from the group consisting of N—{[4—(1H-benzimidazol-5-yloxy)phenyl]methyl}-3-methyl-1-butanamine trifluoroacetate;

N—{[4—(1H-benzimidazol-5-yloxy)phenyl]methyl}-4,4-dimethylcyclohexanamine trifluoroacetate;

N—{[4—(1H-benzimidazol-5-yloxy)phenyl]methyl}-2-(3-fluorophenyl) ethanamine trifluoroacetate;

N—{[4—(1H-benzimidazol-5-yloxy)phenyl]methyl}-2-(2-thienyl)ethanamine trifluoroacetate;

{[4—(1H-benzimidazol-5-yloxy)phenyl]methyl}cyclohexylmethyl)amine trifluoroacetate;

N—{[4—(1H-benzimidazol-5-yloxy)phenyl]methyl}cycloheptanamine trifluoroacetate;

N—{[4—(1H-benzimidazol-5-yloxy)phenyl]methyl}-2-(tetrahydro-2H-pyran-4-yl) ethanamine trifluoroacetate;

(Cyclohexylmethyl){[4-(1H-indazol-5-yloxy)phenyl]methyl}amine hydrochloride; and

[2-(3-fluorophenyl)ethyl]{[4-(1H-indazol-5-yloxy)phenyl]methyl}amine hydrochloride.

6. A pharmaceutical composition comprising (i) a compound of claim 1 , or a pharmaceutically acceptable salt thereof and (ii) at least one carrier.

7. A method of treatment of a condition selected from the group consisting of obesity, diabetes, hypertension, depression, anxiety, drug addiction, and substance addiction comprising administering to a mammal a therapeutically effective amount of a pharmaceutical composition comprising (i) a compound of claim 1 , or a pharmaceutically acceptable salt thereof and (ii) at least one carrier.

8. The method of claim 7 wherein the mammal is a human.

9. A method of treatment of a condition selected from the group consisting of obesity, diabetes, hypertension, depression, anxiety, drug addiction, and substance addiction comprising administering to a mammal a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

10. The method of claim 9 wherein the mammal is a human.

11. The method of claim 7 wherein said treatment is for the condition of obesity.

12. A compound of claim 1 , or a pharmaceutically acceptable salt thereof in combination with at least one other species for treating obesity wherein said other species for treating obesity is an agent or drug selected from the group of consisting of human ciliary neurotropic factor, a CB-1 antagonist or inverse agonist, a neurotransmitter reuptake inhibitor, a lipase inhibitor, an MC4R agonist, a 5-HT2c agonist, a ghrelin receptor antagonist, a CCK-A receptor agonist, an NPY Y1 antagonist, PYY 3 -36 , and a PPAR activator.

13. A process for the preparation of a pharmaceutical formulation comprising admixing a compound of claim 1 or a salt thereof, with one or more pharmaceutical excipients.